Clinical Practice Session
Role of Hemoadsorption in Extracorporeal Blood Purification
October 22, 2026 | 04:30 PM - 06:00 PM
Location: Four Seasons Ballroom 4, Convention Center
Session Description
Hemoadsorption is an emerging extracorporeal therapy that removes inflammatory mediators, endotoxins, and select circulating compounds from critically ill patients. This session reviews the mechanisms of hemoadsorption and critically examines clinical evidence for its use in cardiac surgery-associated AKI, endotoxic septic shock, and maintenance hemodialysis. Experts also address considerations for drug removal and practical issues in patient selection, timing, and integration into extracorporeal circuits.
Learning Objective(s)
- Describe the core mechanisms of hemoadsorption, including sorbent properties, and how these inform clinical use of extracorporeal blood purification
- Evaluate the rationale and clinical evidence for styrene-divinylbenzene hemoadsorption in cardiac surgery-associated AKI
- Assess the mechanisms and evidence supporting polymyxin B hemoadsorption for endotoxin removal in gram-negative sepsis
- Discuss the emerging role of hemoadsorption in maintenance hemodialysis, including effects on inflammation and symptoms
- Discuss how hemoadsorption can be integrated into clinical decision-making, including patient selection, timing, drug removal considerations, and procedural limitations
Learning Pathway(s)
- AKI and Critical Care
- Dialysis
Moderators
Presentations
- Hemoadsorption with Polymyxin B Cartridges in Endotoxic Septic Shock
04:30 PM - 04:50 PM
- Hemoadsorption During Cardiac Bypass for Preventing AKI
04:50 PM - 05:10 PM
- Hemoadsorption in Patients Receiving Maintenance Hemodialysis or Hemodiafiltration
05:10 PM - 05:30 PM
- Hemoadsorption in Patients Receiving Ticagrelor or Factor Xa Inhibitors
05:30 PM - 05:50 PM
- Q&A
05:50 PM - 06:00 PM